Authors: Stephanie Seneff 1, Greg Nigh 2, Anthony M Kyriakopoulos 3, Peter A McCullough 4 PMID: 35436552 PMCID: PMC9012513 DOI: 10.1016/j.fct.2022.113008 Abstract The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide the mRNA from cellular […]